Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on uniQure to $46 from $53 and keeps a Buy rating on the shares. Following the AMT-130 update, AMT-130 is “now a show-me story,” but positive evolution of the clinical signal from the follow-up data in Q4 “could be the redemption,” the analyst tells investors. Additionally, the current negative $200M enterprise value “undercuts” future royalties and milestones from Hemgenix and other pipeline initiatives should be ready for clinical debut in 2023, argues Guggenheim.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QURE:
- uniQure price target lowered to $14 from $24 at Wells Fargo
- uniQure price target lowered to $27 from $45 at Chardan
- uniQure selloff on AMT-130 update ‘appears overdone,’ says H.C. Wainwright
- uniQure Tanks on Interim Data in Huntington’s Disease
- uniQure announces update on Phase I/II trial of AMT-130